Featured Product
This Week in Quality Digest Live
Health Care Features
Merilee Kern
Radicle Science brings AI-driven clinical trials to cannabinoid and wellness research
Duxin Sun
Working at such small scale becomes the next big thing
Dario Lirio
Modernization is critical to enhance patient experience and boost clinical trial productivity
Alexander Khomich
Healthcare software opens up opportunities for clinics in both management and patient care
Gary Shorter
Pharma needs to adapt and evolve with the changing environment of life science data

More Features

Health Care News
Winter 2022 release of Reliance QMS focuses on usability, mobility, and actionable insights
The tabletop diagnostic yields results in an hour and can be programmed to detect variants of the SARS-CoV-2 virus
First Responder UAS Triple Challenge focuses on using optical sensors and data analysis to improve image detection and location
Free education source for global medical device community
Extended validation of Thermo Scientific Salmonella Precis Method simplifies workflows and encompasses challenging food matrices
‘Completely new diagnostic platform’ could prove to be a valuable clinical tool for detecting exposure to multiple viruses
Provides improved thermal stability for stored materials, risk mitigation advantages, and processes that are documented and repeatable
Patient safety is a key focus in update of ISO 14155, the industry reference for good practice in clinical trials.
Despite being far from campus because of the pandemic, some students are engineering a creative way to stay connected

More News

Health Care

Backlash Against Johnson & Johnson’s Covid-19 Vaccine Is Real and Risky

Here’s how to make its rollout a success

Published: Monday, March 29, 2021 - 12:02

More than 50 million Americans have received at least one dose of either the Pfizer or Moderna Covid-19 vaccine. So far, Americans have been largely brand-agnostic, but that’s about to change as the Johnson & Johnson vaccine rolls out.

The vaccine has been hailed as a game changer. It requires only a single dose rather than two doses spaced weeks apart, and it does not need freezer storage, making it a natural fit for hard-to-reach rural areas and underserved communities with limited access to healthcare and storage facilities.

But while many people are excited about the prospects of only one shot, the new vaccine is also getting a backlash. Part of that is coming from lack of clarity about the vaccine’s efficacy numbers, and part of it is more nuanced. On March 2, 2020, the U.S. Conference of Catholic Bishops urged Catholics to avoid the Johnson & Johnson vaccine because it uses lab-grown cells that are clones of fetal tissue from abortions in the 1980s.

If states don’t plan carefully for how the vaccines are distributed, the result could be a nightmare of frustrated patients and wasted vaccine.

As experts specializing in healthcare operations, data analytics, and supply chain management, we have been analyzing Covid-19 vaccine rollout policies. Although our research shows there is great promise for the one-dose vaccine, we believe biases against the Johnson & Johnson vaccine cannot be ignored in planning and distribution decisions.

The problem with comparing efficacy numbers

The primary factor complicating acceptance of the Johnson & Johnson vaccine is in the top-line number: It has an efficacy level of 66 percent, while the other two U.S.-authorized vaccines, made by Pfizer and Moderna, have efficacy levels of at least 90 percent.

Trying to compare those numbers is tricky, though. Experts are quick to point out that the clinical trials were conducted at different times; Pfizer and Moderna conducted their trials before several other mutated variants had been reported, whereas Johnson & Johnson’s trials were conducted after that. Consequently, Johnson & Johnson has clinical trial data to show its vaccine can work effectively against variants first reported in the United Kingdom, South Africa, and Brazil.

In terms of preventing severe disease, hospitalization, and death, the Johnson & Johnson vaccine is comparable to the Pfizer and Moderna vaccines. With continued shortage of vaccine supply, individuals and vaccinators should take any one of the three vaccines whenever they are available so that they can get sufficient protection sooner.

Yet the sheer difference in the top-line numbers makes it difficult to look away. According to a February 2021 Centers for Disease Control and Prevention survey, when offered the choice between a two-dose Covid-19 vaccine, either Pfizer or Moderna, and a one-dose vaccine, Johnson & Johnson’s, nearly 60 percent of the respondents preferred the two-dose vaccine and only 7 percent preferred the one-dose vaccine. Among those who preferred two-dose vaccines, 72 percent said they were willing to wait a month for it rather than get the one-dose vaccine now.

Such biases can have real consequences. In the European Union, 80 percent of the Covid-19 vaccine doses made by AstraZeneca—which also has lower reported efficacy and isn’t authorized in the U.S.—were sitting on the shelves. Many people, including some clinicians, reportedly believe it to be inferior to the Pfizer vaccine.

Four strategies for a successful rollout

A one-dose vaccine would be ideal for hard-to-reach rural areas and underserved communities. Meatpacking companies have reached out to officials in North Carolina, for example, and the state plans to target agricultural workers. But distributing only the Johnson & Johnson vaccine now could compound the already deep-seated vaccine hesitancy in some regions.

Policymakers must acknowledge these fears and develop a plan. Here are four strategies for creating as smooth a rollout as possible.

1. Let people know which vaccine they will be getting when they book the appointment. That can avoid people rejecting vaccines at the distribution site, which leads to wasted appointment time slots and potentially wasted vaccine doses. When only the two mRNA vaccines were available, many states did not reveal the vaccine brand when offering appointments, and the public largely perceives the two as interchangeable products.

2. Have each vaccination site focus on one type of vaccine, either the Johnson & Johnson vaccine or the Pfizer or Moderna two-dose vaccines, to avoid confusion for recipients. Separating vaccine offerings can respect people’s legitimate preferences and avoid last-minute cancellations. Operationally speaking, focusing on a single type of vaccine also simplifies the administration process and prevents handling errors.

3. The Johnson & Johnson vaccine is suitable for small-scale and mobile vaccination sites in rural areas and underserved communities, as well as individuals. However, health officials can help avoid some backlash if they ensure people are offered the option to travel a reasonable distance to larger vaccination sites that offer the Pfizer and Moderna vaccines. Letting people make informed decision can avoid public mistrust.

4. Instead of avoiding comparing the three vaccines, public health experts should be more transparent in educating the public about the effectiveness of the Johnson & Johnson vaccine. For example, the single-dose vaccine is believed to be 100-percent effective in preventing hospitalizations and deaths from Covid-19.

The Johnson & Johnson vaccine is a strong boost to the Covid-19 vaccination effort in the United States. However, it may well lead to frustration and waste if vaccine planners don’t prepare for potential biases against this new vaccine. The focus should be to leverage the three vaccines to achieve herd immunity rapidly so that the United States can finally leave the prolonged pandemic behind.

This article is republished from The Conversation under a Creative Commons license. Read the original article.


About The Authors

Tinglong Dai’s picture

Tinglong Dai

Tinglong Dai is an associate professor of operations management and business analytics at Johns Hopkins Carey Business School, Johns Hopkins University School of Nursing.

Christopher Tang’s picture

Christopher Tang

Christopher Tang is the Distinguished Professor and Edward W. Carter Chair in Business Administration at the University of California, Los Angeles.

Ho-Yin Mak’s picture

Ho-Yin Mak

Ho-Yin Mak is an associate professor in management science at the University of Oxford.